NCT02759588View on ClinicalTrials.gov

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions
Ovarian CancerPeritoneal CarcinomatosisFallopian Tube Cancer
Interventions
BIOLOGICAL

GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab

GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.

Trial Locations (2)

32804

AdventHealth Cancer Institute, Orlando

92663

Gynecologic Oncology Associates, Newport Beach

Sponsors
All Listed Sponsors
lead

Genelux Corporation

INDUSTRY